APPLICATION DEADLINE: 9/15/12 - Drug Information Association Philanthropy Program

Drug Information Association Philanthropy ProgramSOURCE: Drug Information Association (DIA)
APPLICATION DEADLINE: 9/15/12.
$ AVAILABLE: Funding requests may not exceed $25,000.
ELIGIBILITY: Applications will be accepted from organizations around the globe that represent 501(c)(3) organizations or registered patient-centered nonprofit charities and serve constituents with:
* Major diseases.
* Rare/Orphan diseases.
* Diseases with limited or no treatment options.
2011-2012 grant recipients are not eligible.
PURPOSE: The Drug Information Association (DIA) is accepting applications for grants through its Philanthropy Program, focusing this year on charitable organizations that increase the knowledge and understanding of patient groups, government, and industry about key issues related to patient-centered health care; developing the capacity of patient groups to lead and facilitate for change; and improving alliances between patient groups and other health care stakeholders.
CONTACT: Stephanie Robinson, (215) 442-6159, e-mail: Stephanie.Robinson@diahome.org. For more information see http://www.diahome.org/en/About-DIA/Mission/~/media/8C9A58CE51B3470E8CE0EF730622D884.ashx
From Drug Information Association e-mail (Medina), 5/24/12
Subject(s) medical research, community health services

The Burrill Report see page 5 of 35 page April report

Downturn Raises Profile of Government and Foundations as Sources of Early-Stage Funding

Grants and contracts can provide financing for ventures too risky for traditional investors

By Linda Molnar

At a time when early-stage life sciences companies face challenges raising money, they are increasingly finding the federal government and foundations can be good sources of non-dilutive funding. This was not always the case. As recent as five years ago, there was a large disconnect between these sources of funding and traditional venture capital, let alone entrepreneurs themselves.

The deep recession that began in 2008 and the significant fall-off in early-stage venture deals and investments have helped to change this. The venture capital world has still not returned to the levels of funding of early-stage life sciences companies of the past years and may never return to those levels given the changes the venture capital industry is undergoing today.